In Q2, the FDA approved two biosimilars in the ustekinumab and bevacizumab markets and four biosimilars were launched within ...

Guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed ...

While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...

Ustekinumab may be more effective than anti-tumor necrosis factor (anti-TNF) therapies in achieving clinical remission among patients with Crohn-like disease of the pouch (CLDP), according to study ...

Ustekinumab is more efficacious than vedolizumab or anti-TNFs as second- or third-line biologic therapy for perianal Crohn disease.

Ustekinumab (Stelara), an IL-12 and IL-23 antagonist, is currently indicated to treat psoriatic arthritis, moderately to severely active Crohn disease, and moderate to severe plaque psoriasis.

86% of the ustekinumab group and 91% of the crossover group saw at least a 50% improvement in their joint pain and inflammation. 79% of the ustekinumab group and 100% of the crossover group benefitted ...

Ustekinumab is an interleukin-12 and interleukin-23 antagonist indicated for the treatment of moderately to severely active Crohn disease or ulcerative colitis. Other indications include active ...

Though earlier clinical trials have suggested ustekinumab (Stelara®) may be an effective therapy for the treatment of systemic lupus erythematosus, the latest research findings call the drug’s ...

Ustekinumab has a possibility to interact with more drugs. These interactions are harmful. Drug interactions can be prevented by avoiding unwanted drug combinations.

In the analysis, the persistence rate was 40.9% at 1 year for ustekinumab compared with 59.1% for secukinumab. At 2 years, the rate was 25.5% for ustekinumab compared with 36.9% for secukinumab.

In the study, 929 patients with moderate to severe psoriasis treated with either brodalumab (n = 339) or ustekinumab (n = 590) were assessed for skin clearance and QOL, as measured by a 100% ...